Literature DB >> 17673370

Comparative plasma disposition of fenbendazole, oxfendazole and albendazole in dogs.

C Gokbulut1, A Bilgili, B Hanedan, Q A McKellar.   

Abstract

The plasma disposition of fenbendazole (FBZ), oxfendazole (OFZ) and albendazole (ABZ); and the enantiospecific disposition of OFZ, and ABZSO produced were investigated following an oral administration (50 mg/kg) in dogs. Blood samples were collected from 1 to 120 h post-administration. The plasma samples were analysed by high performance liquid chromatography (HPLC). The plasma concentration of FBZ, OFZ, ABZ and their metabolites were significantly different from each other and depended on the drug administered. The sulphone metabolite (FBZSO2) of FBZ was not detected in any plasma samples and the parent molecule ABZ did not reach quantifiable concentrations following FBZ and ABZ administration, respectively. OFZ and its sulphone metabolite attained a significantly higher plasma concentration and remained much longer in plasma compared with FBZ and ABZ and their respective metabolites. The maximum plasma concentrations (Cmax), area under the concentration time curve (AUC) and mean residence time (MRT) of parent OFZ were more than 30, 68 and 2 times those of FBZ, respectively. The same parameters for ABZSO were also significantly greater than those of FBZSO. The ratio for total AUCs of both the parent drug and the metabolites were 1:42:7 for following FBZ, OFZ and ABZ administration, respectively. The enantiomers were never in racemic proportions and (+) enantiomers of both OFZ and ABZSO were predominant in plasma. The AUC of (+) enantiomers of OFZ and ABZSO was, respectively more than three and seven times larger than that of (-) enantiomers of both molecules. It is concluded that the plasma concentration of OFZ was substantially greater compared with FBZ and ABZ. The data on the pharmacokinetic profile of OFZ presented here may contribute to evaluate its potential as an anthelmintic drug for parasite control in dogs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673370     DOI: 10.1016/j.vetpar.2007.06.028

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  11 in total

Review 1.  Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.

Authors:  Armando E Gonzalez; Ellen E Codd; John Horton; Hector H Garcia; Robert H Gilman
Journal:  Expert Rev Anti Infect Ther       Date:  2018-12-10       Impact factor: 5.091

2.  Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses.

Authors:  Thanh Bach; Daryl J Murry; Larissa V Stebounova; Gregory Deye; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Inclusion complex and nanoclusters of cyclodextrin to increase the solubility and efficacy of albendazole.

Authors:  P A Pacheco; L N C Rodrigues; J F S Ferreira; A C P Gomes; C J Veríssimo; H Louvandini; R L D Costa; L M Katiki
Journal:  Parasitol Res       Date:  2018-01-11       Impact factor: 2.289

4.  Enantiomerical pharmacokinetic prevalence of (+) albendazole sulphoxide in Trichinella spiralis muscle larvae.

Authors:  Juan José García-Rodríguez; María Carmen Del Vegas-Sánchez; Juan José Torrado-Durán; Francisco Bolás-Fernández
Journal:  Parasitol Res       Date:  2011-08-16       Impact factor: 2.289

5.  Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study.

Authors:  Thanh Bach; Shirley Galbiati; Jessie K Kennedy; Gregory Deye; Effie Y H Nomicos; Ellen E Codd; Hector H Garcia; John Horton; Robert H Gilman; Armando E Gonzalez; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

6.  Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies.

Authors:  Ellen E Codd; Hanna H Ng; Claire McFarlane; Edward S Riccio; Rupa Doppalapudi; Jon C Mirsalis; R John Horton; Armando E Gonzalez; H Hugo Garcia; Robert H Gilman
Journal:  Int J Toxicol       Date:  2015-02-20       Impact factor: 2.032

7.  Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis.

Authors:  Thanh Bach; Gregory A Deye; Ellen E Codd; John Horton; Patricia Winokur; Guohua An
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.938

8.  Comparative pharmacokinetics and bioavailability of albendazole sulfoxide in sheep and goats, and dose-dependent plasma disposition in goats.

Authors:  Dilek Aksit; Hande Sultan Yalinkilinc; Selim Sekkin; Murat Boyacioğlu; Veli Yilgor Cirak; Erol Ayaz; Cengiz Gokbulut
Journal:  BMC Vet Res       Date:  2015-05-27       Impact factor: 2.741

9.  Comparative plasma exposure of albendazole after administration of rapidly disintegrating tablets in dogs.

Authors:  Silvina G Castro; Alicia Dib; Gonzalo Suarez; Daniel Allemandi; Carlos Lanusse; Sergio Sanchez Bruni; Santiago D Palma
Journal:  Biomed Res Int       Date:  2013-08-25       Impact factor: 3.411

10.  Evaluation of oxfendazole in the treatment of zoonotic Onchocerca lupi infection in dogs.

Authors:  Vito Colella; Carla Maia; André Pereira; Nuno Gonçalves; Marta Caruso; Coralie Martin; Luís Cardoso; Lenea Campino; Ivan Scandale; Domenico Otranto
Journal:  PLoS Negl Trop Dis       Date:  2018-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.